Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer

  • 73 Accesses

  • 41 Citations

Abstract

In the management of rectal cancer after the combined therapy of the radiation and surgical operation, the evaluation of the prognosis is important. Although fluoro-18-deoxy glucose positron emission tomography (FDG-PET) is considered as a useful tool for evaluation of therapeutic effect of this cancer as well as the other cancers, however, there are few articles that clearly describe the appropriate procedure of the FDG-PET in order to obtain the best prognostic value. The purpose of the present study is to compare several variations of a semi-quantification method, the Standardized Uptake Values (SUV) and to determine the most appropriate parameter for the prognostic prediction and to propose the quantitative guideline of the FDG-PET. Especially, the authors focused on the SUV after radiotherapy, which had not been considered as a key quantitative value, as it was rather taken as a mere indicator of the therapeutic (radiotherapeutic) effect, not a direct indicator of the prognosis for the cancer itself.Methods: Forty patients with rectal cancer in the lower rectal region underwent two series of FDG-PET study before and after pre-operative radiotherapy. Their SUVs were calculated from FDG-PET data and compared with the results of the long-term follow-up of the patients as well as with histopathological outcomes.Results: All 40 patients had high FDG uptake before radiotherapy. The mean value of SUV before radiotherapy (SUV1) was 7.6. After radiotherapy, the mean value of SUV (SUV2) decreased to 4.2. There was a significant difference in SUV2 between the groups with and without recurrence (p<0.05), however, SUV1 or SUV ratio (SUV2/SUV1) displayed no significant difference with the incidence of recurrence.Conclusion: SUV2 was considered to be a good prognostic indicator for long-term prognosis of rectal cancer patients. SUV1 nor SUV ratio SUV2/SUV1 did not have the equivalent prognostic usefulness. Subsets of patients with SUV2 greater than 3.2 should be observed closely.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001.CA Cancer J Clin 2001; 51: 15–36.

  2. 2.

    Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJ, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytic methods.Eur J Nucl Med 2000; 27: 731–743.

  3. 3.

    Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. [Review]Seminar Oncol 1999; 26: 577–583.

  4. 4.

    Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings.Radiol 1998; 206: 755–760.

  5. 5.

    Fong Y, Saldinder PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.Am J Surg 1999; 178: 282–287.

  6. 6.

    Haberkom U, Strauss LG, Dimitrakopoupou A, Seiffert E, Oberdorfer F, Ziegler S, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy.J Nucl Med 1993; 34: 12–17.

  7. 7.

    Bender H, Bandard N, Metten, N, Bandard M, Mezger J, Schomburg A, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.Hybridoma 1999; 18: 87–91.

  8. 8.

    Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.J Clin Oncol 1996; 14: 700–708.

  9. 9.

    Lai DTM, Fulham M, Stephan MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]Fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.Arch Surg 1996; 131: 703–707.

  10. 10.

    General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. (6th edition) [ed.] Japanese Society for Cancer of the Colon and Rectum, 1998.

  11. 11.

    Ehrenkaufer RL, Potocki JF, Jewett DM. Simple synthesis of F-18 labeled 2-fluoro-2-deoxy-d-glucose.J Nucl Med 1989; 25: 333–337.

  12. 12.

    Iida H, Miura S, Kanno I, Murakami M, Takahashi K, Yamamoto S, et al. Design and evaluation of HEADTOME-IV, a whole-body positron emission tomograph.IEEE Trans Nucl Sci 1989; 36: 1006–1010.

  13. 13.

    Zasadny KR, Wahl LW. Standardized uptake values of normal tissues at PET with 2-[Fluorine-18]-Fluoro-2-deoxy-d-glucose: Variations with body weight and a method for correction.Radiology 1993; 189: 847–850.

  14. 14.

    Keyes JW. SUV: standard uptake or silly useless value?J Nucl Med 1995; 36: 1836–1839.

  15. 15.

    Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction.Radiol 1999; 213: 521–525.

  16. 16.

    Metz CE. Basic principles of ROC analysis.Semin Nucl Med 1978; 4: 283–298.

  17. 17.

    Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies.Invest Radiol 1989; 24: 234–245.

  18. 18.

    Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.J Clin Endocrinol Metab 2000; 85: 1107–1113.

  19. 19.

    Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.J Nucl Med 1988; 39: 1002–1007.

  20. 20.

    Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.J Nucl Med 1997; 1907–1911.

  21. 21.

    Ichiya T, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to chemotherapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.J Nucl Med 1991; 32: 1655–1660.

Download references

Author information

Correspondence to Shinya Oku M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Oku, S., Nakagawa, K., Momose, T. et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 16, 409 (2002). https://doi.org/10.1007/BF02990079

Download citation

Key words

  • FDG-PET
  • Standardized Uptake Value
  • rectal cancer
  • prognostic indicator